La chaîne d'options affiche les données clés des options sur actions de Calidi Biotherapeutics à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Calidi Biotherapeutics..

Calidi Biotherapeutics (AMEX:CLDI) Stock, Chaîne d'Options

Calidi Biotherapeutics

Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.

Calidi Biotherapeutics, Inc. Common Stock

Calidi Biotherapeutics Inc

News

Dividends

ILPT

Industrial Logistics Properties Trust Increases Quarterly Dividend From $0.01/Share To $0.05/Share

BYRN

Byrna Technologies Q2 GAAP EPS $0.10 Beats $0.06 Estimate, Sales $28.50M Beat $28.16M Estimate

<h3>Gainers</h3>
<ul>
<li>Sunlands Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STG#NYSE">STG</a>) shares increased by 11.5% to $8.21 during Thursday's pre-market session. The market value of their outstanding shares is at $99.5 million. </li>
<li>Genius Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GNS#AMEX">GNS</a>) shares moved upwards by 10.71% to $1.55. The company's market cap stands at $100.1 million. </li>
<li>Bassett Furniture Indus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSET#NASDAQ">BSET</a>) stock increased by 10.53% to $18.78. The company's market cap stands at $149.5 million. As per the press release, Q2 earnings came out yesterday. </li>
<li>Birks Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BGI#AMEX">BGI</a>) shares moved upwards by 7.6% to $0.99. The market value of their outstanding shares is at $17.6 million. </li>
<li>AYRO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AYRO#NASDAQ">AYRO</a>) shares moved upwards by 7.33% to $7.3. The market value of their outstanding shares is at $3.6 million. </li>
<li>Viomi Technology Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIOT#NASDAQ">VIOT</a>) shares moved upwards by 6.83% to $2.5. The market value of their outstanding shares is at $159.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Helen Of Troy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HELE#NASDAQ">HELE</a>) stock declined by 26.1% to $22.9 during Thursday's pre-market session. The market value of their outstanding shares is at $711.6 million. As per the news, the Q1 earnings report came out today. </li>
<li>EpicQuest Education Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EEIQ#NASDAQ">EEIQ</a>) stock decreased by 15.66% to $0.53. The company's market cap stands at $8.3 million. </li>
<li>TCTM Kids IT Education (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSA#NASDAQ">VSA</a>) stock fell 7.93% to $0.93. The company's market cap stands at $10.0 million. </li>
<li>Bath &amp; Body Works (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBWI#NYSE">BBWI</a>) stock fell 7.41% to $30.51. The company's market cap stands at $6.9 billion. </li>
<li>Perfect Moment (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PMNT#AMEX">PMNT</a>) stock decreased by 5.99% to $0.3. </li>
<li>Mobileye Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBLY#NASDAQ">MBLY</a>) stock decreased by 5.61% to $16.35. The company's market cap stands at $14.0 billion. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AYRO

BBWI

BSET

EEIQ

HELE

MBLY

PMNT

VIOT

12 Consumer Discretionary Stocks Moving In Thursday's Pre-Market Session

Ligand Pharmaceuticals Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGND#NASDAQ">LGND</a>) today announced that its partner Pelthos Therapeutics Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PTHS#NYSE">PTHS</a>) has commercially launched ZELSUVMI&#x2122; (berdazimer) topical gel 10.3%, the first and only FDA-approved at-home treatment for molluscum contagiosum. The Company has earned a $5 million milestone payment from Pelthos following the commercial launch of ZELSUVMI.
Following the completion of the merger between Pelthos Therapeutics and Channel Therapeutics in July 2025, Ligand now owns 56% of Pelthos. Additionally, under the terms of the license agreement with Pelthos, Ligand is entitled to a 13% royalty on worldwide sales of ZELSUVMI and up to an additional $5 million in commercial sales milestones.

LGND

PTHS

Ligand Pharm's Partner Pelthos Therapeutics Commercially Launches ZELSUVMI Topical Gel 10.3%, FDA-Approved At-Home Treatment For Molluscum Contagiosum

<h3>Gainers</h3>
<ul>
<li>Cognition Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTX#NASDAQ">CGTX</a>) shares rose 45.7% to $0.78 during Thursday's pre-market session. The market value of their outstanding shares is at $32.9 million. </li>
<li>Klotho Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLTO#NASDAQ">KLTO</a>) stock moved upwards by 22.62% to $1.68. The market value of their outstanding shares is at $49.9 million. </li>
<li>IGC Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IGC#AMEX">IGC</a>) stock rose 21.91% to $0.45. The market value of their outstanding shares is at $29.1 million. </li>
<li>ProKidney (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PROK#NASDAQ">PROK</a>) stock moved upwards by 17.97% to $5.12. The market value of their outstanding shares is at $562.1 million. </li>
<li>Nurix Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRIX#NASDAQ">NRIX</a>) stock rose 16.94% to $15.41. The company's market cap stands at $1.0 billion. The company's, Q2 earnings came out yesterday. </li>
<li>Liminatus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIMN#NASDAQ">LIMN</a>) shares moved upwards by 16.47% to $6.08. The market value of their outstanding shares is at $135.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Mereo BioPharma Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MREO#NASDAQ">MREO</a>) shares decreased by 31.0% to $2.03 during Thursday's pre-market session. The company's market cap stands at $467.4 million. </li>
<li>Creative Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELZ#NASDAQ">CELZ</a>) shares fell 26.91% to $2.88. The market value of their outstanding shares is at $10.1 million. </li>
<li>Ultragenyx Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>) stock decreased by 20.37% to $33.0. The company's market cap stands at $3.9 billion. </li>
<li>Basel Medical Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMGL#NASDAQ">BMGL</a>) shares declined by 18.79% to $2.94. The market value of their outstanding shares is at $68.0 million. </li>
<li>Passage Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PASG#NASDAQ">PASG</a>) stock declined by 18.37% to $0.36. The market value of their outstanding shares is at $27.4 million. </li>
<li>Aethlon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) stock fell 16.6% to $1.21. The market value of their outstanding shares is at $2.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AEMD

BMGL

CELZ

CGTX

KLTO

LIMN

MREO

NRIX

PASG

PROK

RARE

12 Health Care Stocks Moving In Thursday's Pre-Market Session

<a href="https://www.globenewswire.com/Tracker?data=g4IOPZosuJui9oW-6uel1y1KJQtKaQIdrxo6FTzeQUgpFhQOjCYEf1umEWAB8ATjV-atvawXlIDazg7nnPSM3JIvTv5Eaa3lZfxQ70GwSh4=">Genius Group Limited</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNS#NYSE">GNS</a>) ("Genius Group" or the "Company"), a leading AI-powered, Bitcoin-first education group, today announced that further to receiving shareholder and board approval for a share buyback of up to 20% of the Company's issued ordinary shares, on July 9, 2025 the Company bought back one million shares of its stock on the open market at an average price of $1.30 per share.
At Genius Group's Annual General Meeting (AGM) on July 7, 2025, Company shareholders voted 98.8% in favor of a proposed share buyback mandate which authorizes the Board to buy back up to 20% of the Company's issued ordinary shares at any time over the next twelve months or until the Company's next AGM.
Further to the shareholder approval, on July 8, 2025, the Company's Board passed a resolution authorizing the CEO to execute the share buyback for up to 100% of the total shareholder approved buyback limit of up to 20% of the Company's issued Class A Ordinary Shares, in such manner, proportion and timing as he deems most appropriate to preserve shareholder value.
On July 9, 2025, the Company's CEO, Roger Hamilton, executed a buy back of one million shares of the company's ordinary shares at an average price of $1.30 per share.
The one million repurchased shares represent 7% of the permitted shares to be repurchased based on the approved share buy back mandate. The repurchased shares have been returned to the Company's treasury.
In executing the buy back, the Company and the Company's broker followed the guidelines in Rule 10b-18 and Rule 10b-5 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), to ensure compliance and a non-exclusive safe harbor in relation to the repurchase of its shares.
The Company may elect to execute further buy backs within the parameters of its approved mandate in such manner, proportion and timing as it deems most appropriate to preserve shareholder value based on economic and market dynamics, together with the Company's share price relative to the Company's current and anticipated enterprise value and net asset value.

Buybacks

Genius Group Announces Approval And Initiation Of 20% Share Buyback Of 1M Shares At An Average Price Of $1.30/Per Share

<h3>Gainers</h3>
<ul>
<li>Air Industries (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AIRI#AMEX">AIRI</a>) shares increased by 39.2% to $4.58 during Thursday's pre-market session. The market value of their outstanding shares is at $12.3 million. </li>
<li>Delta Air Lines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>) shares moved upwards by 13.6% to $57.6. The market value of their outstanding shares is at $33.1 billion. As per the press release, Q2 earnings came out today. </li>
<li>Micropolis Hldgs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MCRP#AMEX">MCRP</a>) shares moved upwards by 12.43% to $3.22. The market value of their outstanding shares is at $99.9 million. </li>
<li>FuelCell Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCEL#NASDAQ">FCEL</a>) stock rose 9.81% to $6.15. The market value of their outstanding shares is at $127.6 million. </li>
<li>United Airlines Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>) stock moved upwards by 9.37% to $87.7. The market value of their outstanding shares is at $26.1 billion. </li>
<li>American Airlines Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAL#NASDAQ">AAL</a>) shares rose 7.92% to $12.39. The company's market cap stands at $7.5 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Aqua Metals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQMS#NASDAQ">AQMS</a>) shares declined by 8.3% to $0.54 during Thursday's pre-market session. The company's market cap stands at $5.8 million. </li>
<li>Fusion Fuel Green (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTOO#NASDAQ">HTOO</a>) stock fell 6.8% to $0.17. The company's market cap stands at $4.8 million. </li>
<li>Westwater Resources (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/WWR#AMEX">WWR</a>) stock fell 6.44% to $0.57. The market value of their outstanding shares is at $47.3 million. </li>
<li>Armlogi Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTOC#NASDAQ">BTOC</a>) stock decreased by 5.32% to $1.4. The company's market cap stands at $62.3 million. </li>
<li>Ryde Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/RYDE#AMEX">RYDE</a>) shares fell 5.26% to $0.34. The company's market cap stands at $12.2 million. </li>
<li>Alta Equipment Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALTG#NYSE">ALTG</a>) stock fell 5.12% to $8.16. The company's market cap stands at $285.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AIRI

ALTG

AQMS

BTOC

FCEL

HTOO

MCRP

RYDE

12 Industrials Stocks Moving In Thursday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>BIT Mining (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BTCM#NYSE">BTCM</a>) stock moved upwards by 244.3% to $8.47 during Thursday's pre-market session. The market value of their outstanding shares is at $39.2 million. </li>
<li>ARB IOT Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARBB#NASDAQ">ARBB</a>) stock increased by 11.94% to $6.28. The market value of their outstanding shares is at $9.9 million. </li>
<li>U-BX Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UBXG#NASDAQ">UBXG</a>) shares increased by 11.26% to $3.26. The market value of their outstanding shares is at $60.8 million. </li>
<li>Mawson Infra Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIGI#NASDAQ">MIGI</a>) stock moved upwards by 8.49% to $0.53. The company's market cap stands at $9.7 million. </li>
<li>Sequans Communications (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQNS#NYSE">SQNS</a>) stock increased by 7.76% to $2.23. The company's market cap stands at $52.8 million. </li>
<li>Zepp Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZEPP#NYSE">ZEPP</a>) stock rose 7.56% to $5.97. The company's market cap stands at $332.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Methode Electronics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MEI#NYSE">MEI</a>) shares decreased by 18.4% to $8.4 during Thursday's pre-market session. The company's market cap stands at $367.2 million. As per the news, the Q4 earnings report came out yesterday. </li>
<li>BitMine Immersion Techs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BMNR#AMEX">BMNR</a>) shares fell 15.7% to $56.25. The market value of their outstanding shares is at $3.4 billion. </li>
<li>Sobr Safe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOBR#NASDAQ">SOBR</a>) stock fell 13.3% to $4.11. The market value of their outstanding shares is at $7.1 million. </li>
<li>AXT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXTI#NASDAQ">AXTI</a>) stock declined by 11.42% to $2.25. The company's market cap stands at $115.8 million. </li>
<li>Trident Digital Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TDTH#NASDAQ">TDTH</a>) stock decreased by 9.2% to $0.31. The market value of their outstanding shares is at $22.0 million. </li>
<li>Rackspace Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXT#NASDAQ">RXT</a>) shares declined by 7.94% to $1.27. The market value of their outstanding shares is at $327.5 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARBB

AXTI

BMNR

BTCM

MAWSON INFRSTRUCTURE GRP by Mawson Infrastructure Group Inc.

MIGI

SOBR

SQNS

TDTH

UBXG

ZEPP

12 Information Technology Stocks Moving In Thursday's Pre-Market Session

Biotech

General

PDSB

PDS Biotech Completes Patient Recruitment In Stage 1 Of Trial Of PDS01ADC; Study Met Criteria For Expansion Into Stage 2

Northern Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTIC#NASDAQ">NTIC</a>) reported quarterly earnings of $0.02 per share which missed the analyst consensus estimate of $0.04 by 50 percent. This is a 81.82 percent decrease over earnings of $0.11 per share from the same period last year. The company reported quarterly sales of $21.509 million which beat the analyst consensus estimate of $20.700 million by 3.91 percent. This is a 3.98 percent increase over sales of $20.686 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

NTIC

Northern Technologies Q3 Adj. EPS $0.02 Misses $0.04 Estimate, Sales $21.509M Beat $20.700M Estimate

<a href="https://icecure-medical.com/">IceCure Medical Ltd.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICCM#NASDAQ">ICCM</a>) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that it has commenced its previously disclosed rights offering (the "Rights Offering").
Pursuant to the Rights Offering, the Company is distributing to&nbsp;all holders of record of the Company's ordinary shares, no par value per share ("Ordinary Shares") as of 5:00 p.m., Eastern Time, on July 9, 2025 (the "Record Date"), at no charge, non-transferable subscription rights (the "Subscription Rights") to purchase up to an aggregate of 10,000,000 units ("Units") at a subscription price of $1.00 per whole Unit.
Each holder of the Company's Ordinary Shares will receive one Subscription Right for every Ordinary Share owned on the Record Date. Each Subscription Right will entitle its holder to purchase 0.1703 of a Unit, each comprised of one Ordinary Share and a warrant to purchase one Ordinary Share (the "Warrant") at a subscription price of $1.00 per Unit or, in lieu of such Unit, one Unit, each comprised of one pre-funded warrant to purchase one Ordinary Share and one Warrant, at a subscription price of $0.9999 per Unit . No fractional Subscription Rights are being distributed and no fractional Units will be issued upon the exercise of any Subscription Rights in the Rights Offering. Shareholders must exercise Subscription Rights for at least one whole Unit to participate in the Rights Offering. The Subscription Rights will expire if they are not exercised by 5:00 p.m., Eastern Time, on July 28, 2025, the expected expiration date of the Rights Offering. The Company may extend the period for exercising the Subscription Rights. Subscription Rights which are not exercised by the expiration date of the Rights Offering will expire and will have no value.
Assuming the Rights Offering is fully subscribed, the Company expects to receive aggregate gross proceeds of $10 million. Holders who fully exercise their basic Subscription Rights will be entitled to subscribe for additional Units that remain unsubscribed as a result of any unexercised basic Subscription Rights. If over-subscription privilege requests exceed the remaining Units available, the remaining Units will be allocated pro-rata among holders who over-subscribe based on the number of Ordinary Shares held by all holders exercising the privilege.&nbsp;Epoch Partner Investments Limited ("Epoch"), the Company's largest shareholder, has committed to participate in the Rights Offering and exercise its Subscription Right in full and any over-subscription privilege to purchase Units not subscribed for by other shareholders with an aggregate subscription price of up to $5 million. Li Haixiang, the sole director of Epoch, is a member of the board of directors of the Company. As previously announced by the Company on May 21, 2025, Epoch granted IceCure a $2 million unsecured loan on May 17, 2025 bearing interest of 4.05% (the "Bridge Loan"). The Bridge Loan will be repaid after 12 months or upon the completion of the Rights Offering, whichever is earlier. The Company intends to use the proceeds of the Rights Offering, including proceeds directly raised from Epoch's participation in the Rights Offering, to repay the principal and any accrued interest from the Bridge Loan and for general corporate and working capital purposes.

Offerings

ICCM

IceCure Medical Launches $10M Rights Offering To Fund Operations, Repay Bridge Loan

In a market increasingly defined by volatility and uncertainty, investors are grappling with a mix of opportunities and risks. The recent turmoil in the tech sector, particularly among companies heavily reliant <a href="https://www.benzinga.com/topic/artificial-intelligence">on artificial intelligence</a>, has raised questions about sustainability and profitability.
On CNBC's &#8220;Mad Money Lightning Round,&#8221; Jim Cramer said Tempus AI, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>) is another company that's just losing money &#8220;hand over fist,&#8221; so he recommended not <a href="https://www.benzinga.com/general/biotech/25/07/46331040/personalis-and-tempus-extend-partnership-through-2029-add-colorectal-cancer-to-mrd-test-deal-cove">going there</a>.
According to recent news, Personalis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNL#NASDAQ">PSNL</a>) announced on Wednesday an expansion and extension of its strategic collaboration with Tempus AI, adding a new indication, colorectal cancer, to the existing, exclusive commercialization agreement.
When asked about First Majestic Silver Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AG#NYSE">AG</a>), he said, &#8220;I like silver. First Majestic, not familiar with. The one that I've always recommended is Pan American (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAAS#NASDAQ">PAAS</a>) because it's been profitable for a very long time.&#8221;
First Majestic Silver, on Wednesday, issued second-quarter production numbers and raised its FY25 silver and gold outlook.
Insmed Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) is &#8220;very speculative,&#8221; Cramer said. &#8220;It has lost a huge amount of money, so it's very hard for me to get a handle on it.&#8221;
According to recent news, Insmed announced topline results from its randomized, double-blind, placebo-controlled Phase 2b study evaluating the efficacy and safety of treprostinil palmitate inhalation powder on Thursday. The study met its primary endpoint and all secondary efficacy endpoints.
&#8220;I don't think that there's anything investible in, honestly, in autonomous, other than Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>),&#8221; Cramer said when asked about Ouster, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OUST#NASDAQ">OUST</a>). &#8220;I'm going to say no, too speculative.&#8221;
Supporting his view, WestPark Capital analyst Casey Ryan, on June 12, downgraded Ouster from Buy to Hold.
Price Action:
<ul class="wp-block-list">
<li>Tempus AI shares fell 0.2% to settle at $58.41 on Wednesday.</li>
<li>First Majestic Silver shares gained 5.5% to close at $8.43.</li>
<li>Ouster shares gained 6.4% to settle at $24.63 on Wednesday.</li>
<li>Insmed shares rose 0.3% to close at $96.47.</li>
</ul>
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/07/46316741/top-3-risk-off-stocks-that-may-rocket-higher-in-q3">Top 3 Risk Off Stocks That May Rocket Higher In Q3</a></li>
</ul>
Image created using photos from Shutterstock.

Long Ideas

Markets

Media

Trading Ideas

INSM

OUST

PAAS

PSNL

TSLA

Cramer Says Tesla Dominates While Ouster Is 'Too Speculative'

Extensive Clinical Data Continues to Demonstrate VLN&#xAE; Reduced Nicotine Content Tobacco Helps Reduce Smoking and Increase Quit Attempts
Growing List of VLN&#xAE; Based Cigarette Brands Bring Non-Addictive Alternatives to the Fight Against Smoking
MOCKSVILLE, N.C., July 10, 2025 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>), the only tobacco products company that has for 27 years led and continues to lead the fight against the harms of smoking driven by nicotine addiction today announces a corporate update regarding its Modified Risk Tobacco Product renewal process for its innovative VLN&#xAE; reduced nicotine content products - the first and only combustible cigarette authorized by the U.S. Food and Drug Administration specifically to reduce the health harms of smoking.
Originally authorized in December 2021 and due for renewal in December 2026, a growing list of brands are using VLN&#xAE; tobacco containing 95% less nicotine than conventional, highly addictive cigarettes. Decades of independent clinical research studies and an extensive list of peer reviewed publications that were included as part of the FDA's MRTP authorization process have demonstrated that smoking VLN&#xAE; reduced nicotine content cigarettes lowers the amount of addictive nicotine consumed, can reduce the rate of smoking, increase quit attempts by smokers and reduce the health harms of smoking. Based on independent clinical research studies included in the original MRTP decision, FDA authorized VLN&#xAE; claims include:
<ul>
<li>"95% less nicotine"</li>
<li>"Helps reduce your nicotine consumption"</li>
<li>"Greatly reduces your nicotine consumption"</li>
<li>"Helps you smoke less"</li>
</ul>
The renewal process is part of 22nd Century's ongoing R&amp;D programs that continue to advance reduced nicotine content in tobacco and support the introduction of additional VLN&#xAE; based products that give tobacco users further health oriented non-addictive alternatives to conventional tobacco products, as well as to new nicotine delivery products that are designed to create and sustain nicotine addiction.

XXII

22nd Century Group Issues Corporate Update On Modified Risk Tobacco Product Renewal Process For VLN Reduced Nicotine Content Products

BMO Capital analyst Ryan Griffin initiates coverage on TransUnion (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRU#NYSE">TRU</a>) with a Outperform rating and announces Price Target of $115.

Price Target

Initiation

Analyst Ratings

BMO Capital Initiates Coverage On TransUnion with Outperform Rating, Announces Price Target of $115

Contracts

MSFT

Accenture And Microsoft Corporation Announces Co-Investment In The Development Of Advanced Generative AI-Driven Cyber Solutions To Help Organizations Mitigate Threats And Consolidate Technology Tools While Optimizing Operational Costs

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

DDC Enterprise Signs MoU With Animoca Brands Whereby Animoca Will Allocate Up To $100M In Bitcoin Towards Yield Enhancement Strategies Operated By DDC

UBS analyst Thiago Batista downgrades Itau Unibanco Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITUB#NYSE">ITUB</a>) from Buy to Neutral.

Downgrades

ITUB

UBS Downgrades Itau Unibanco Holding to Neutral

Analysts from Jefferies have expressed concerns about&nbsp;Lululemon Athletica Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) moving away from its foundational yoga-inspired ethos, a shift that could potentially pose risks to the company&#8217;s business.
What Happened: Jefferies analysts, after visiting two Lululemon outlets in Westport, Connecticut, and Coral Gables, Florida, identified issues with the brand&#8217;s product line. They observed that Lululemon was heavily relying on large logos and moving significantly away from its yoga origins. The analysts commented, &#8220;LULU&nbsp;continues to stray further away&nbsp;from its yoga-inspired roots to&nbsp;designs similar to general apparel&nbsp;brands like the Gap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GAP#NYSE">GAP</a>),&#8221;&nbsp;<a href="https://www.businessinsider.com/lululemon-problems-jefferies-analysts-logos-sales-colors-2025-7">reported</a>&nbsp;Business Insider.
Check out the current price of <a href="https://benzinga.com/quote/lulu" target="_blank" rel="noreferrer noopener">LULU stock here</a>.
Chip Wilson, the founder and ex-CEO, supported the analysts&#8217; concerns in a Forbes interview earlier this year, stating that the brand&#8217;s offerings were becoming similar to the Gap.&nbsp;
The brand&#8217;s attempts&nbsp;to add new colors and&nbsp;products to address its product struggles resulted in a &#8220;disjointed assortment that&#8217;s failing to convert,&#8221; the analysts noted.&nbsp;This resulted in a 2% decline in Lululemon's comparable sales in the Americas during the first quarter of 2025, along with over 36% plunge in its stock value since the start of the year.
&#8220;Color Palette Goes Sesame Street,&#8221; observed the analysts 
The Jefferies note also highlighted the large volume of discounted items both in stores and online, indicating difficulties with sell-through and a reliance on markdowns to reduce excess inventory.
They also pointed out that the&nbsp;new designs at the two&nbsp;stores featured &#8220;loud&nbsp;colors and large logos in&nbsp;an attempt to sell beyond&nbsp;their core customer and attract&nbsp;younger shoppers,&#8221; which could potentially alienate Lululemon&#8217;s base consumers.
SEE ALSO:&nbsp;<a href="https://benzinga.com/news/legal/25/07/46316016/unitedhealth-whistleblowers-allege-medicare-misconduct" target="_blank" rel="noreferrer noopener">UnitedHealth Former Staff Reveal Dark Secrets Of Medicare Billing Practices</a>
Why It Matters: These concerns from analysts came soon after Lululemon filed a lawsuit against Costco (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>), accusing the retailer of copying designs from some of its best-selling products.
Lululemon&#8217;s recent struggles with its product offerings and sales come on the heels of a <a href="https://www.benzinga.com/trading-ideas/movers/25/06/45803189/lululemon-q1-earnings-revenue-beat-eps-in-line-shares-tumble-on-weaker-earnings-forecast">strong first-quarter </a>performance. The company reported a revenue of $2.37 billion, beating the consensus estimate. However, the stock tumbled after the company&#8217;s weaker earnings forecast.
Following the disappointing guidance, Lululemon&#8217;s stock continued to slide, with analysts&nbsp;<a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/06/45819605/lululemon-stock-tumbles-after-outlook-disappoints-tariffs-markdowns-flagged-by-analysts">flagging</a>&nbsp;tariffs and markdowns as potential issues. The recent report by Jefferies adds to the growing concerns about Lululemon&#8217;s future performance and its ability to maintain its brand identity in the face of increasing competition.
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="766" height="116" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/10064608/image-117.png" alt="" class="wp-image-979895" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/10064608/image-117.png 766w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/10064608/image-117-300x45.png 300w" sizes="(max-width: 766px) 100vw, 766px" /></figure>
Benzinga's Edge Rankings place Lululemon in the 92nd percentile for growth and the 59th percentile for value, reflecting mixed performance. Check the detailed report <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">here</a>.&nbsp;
<ul class="wp-block-list">
<li>READ MORE: &nbsp;<a href="https://benzinga.com/markets/macro-economic-events/25/07/46336626/trump-administration-sues-gavin-newsom-other-state-officials-over-californias-egg-laws-driving-up-prices-nationwide-unnecessary-red-tape" target="_blank" rel="noreferrer noopener">Trump Administration Sues Gavin Newsom, Other State Officials Over California's Egg Laws Driving Up Prices Nationwide: &#8216;Unnecessary Red Tape&#8217; &#8211; Benzinga</a> </li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

COST

LULU

Lululemon's Shift From Yoga-Inspired Roots May Be The Cause Of Dipping Comparable Sales, Warn Analysts: 'Color Palette Goes Sesame Street'

BMO Capital analyst Ryan Griffin initiates coverage on Equifax (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EFX#NYSE">EFX</a>) with a Market Perform rating and announces Price Target of $280.

BMO Capital Initiates Coverage On Equifax with Market Perform Rating, Announces Price Target of $280

Fusion Fuel Green Announces 1-For-35 Reverse Share Split To Regain Compliance With Nasdaq's Minimum Bid Price Rule

Press Releases

Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711

Health Care

Calidi Biotherapeutics Announces IL15 Superagonist as First Payload to be Delivered by Systemic Antitumor Virotherapy  Platform at AACR Annual Meeting

Calidi Biotherapeutics Reports First Quarter 2025 Financial Results and Recent Operational Highlights

Calidi Biotherapeutics Presents systemic oncolytic platform with CD55-Enhanced expression and IL-15 Superagonist Payload at ASCO Annual Meeting

Calidi Biotherapeutics Announces Shareholder Letter from CEO

Small Cap

Opinion

Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Developing Precision Genetic Medicine Platform for Cancer Treatment

Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers

Financing

Calidi Biotherapeutics Announces Exercise of Warrants for $4.6 Million of Gross Proceeds

CGON

CLDI

CRSP

CTMX

IBRX

MTEM

REGN

RHHBF

RHHBY

VRTX

Apimeds Pharmaceuticals US, Inc. Common Stock

Apimeds Pharmaceuticals

BioAtla

BioLineRx Ltd. - American Depositary Shares

BioLine Rx

Carisma Therapeutics, Inc. - Common Stock

CARISMA Therapeutics

CASI Pharmaceuticals, Inc. - Ordinary Shares

CASI Pharmaceuticals

CollPlant Biotechnologies Ltd. - Ordinary Shares

CollPlant Biotechnologies

Chemomab Therapeutics Ltd. - American Depositary Shares

Chemomab Therapeutics

Curis

Elevation Oncology

FibroGen

Generation Bio

Geovax Labs

Longeveron

LakeShore Biopharma Co., Ltd - Ordinary Shares

LakeShore Biopharma

Lisata Therapeutics

MEI Pharma

Marker Therapeutics

NuCana

Nanoviricides

OSR Holdings

Plus Therapeutics

Q32 Bio

Rallybio

SAB Biotherapeutics

Tenax Therapeutics

Ladenburg Thalmann

Baird

HC Wainwright & Co.

Screenshot 2024-03-05 at 6.31.45 PM

CADL

TOVX

Could This Common Virus Unlock New Cancer Treatments? Theriva Biologics Believes That Adenoviruses Could Be Instrumental In The Next Evolution Of Oncology

Comments

Calidi Biotherapeutics

Calidi Biotherapeutics (CLDI) Options

No option chain data available. Please try again later

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL